VIVANI MEDICAL INC (VANI) Stock News
NASDAQ:VANI - Nasdaq - US92854B1098 - Common Stock - Currency: USD
VANI Latest News, Press Relases and Analysis
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical...
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam...
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and...
Do You Believe in Columbus McKinnon Corp.’s (CMCO) Compelling Risk/Reward Opportunity?
Heartland Advisors, an investment management company, released its “Heartland Value Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund was down 5.63% in the first quarter compared to a 7.74% fall for the Russell 2000 Value Index. The fund outperformed the benchmark over the past 1, 3, […]
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vivani Medical (NASDAQ:VANI) just reported results for the second quarter of 20...
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024
VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects...
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once...
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars
The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide...
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
